Navigation Links
Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare Conference
Date:11/10/2010

SAN DIEGO, Nov. 10, 2010 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an update on Marshall Edwards and its lead oncology programs at the Lazard Capital Markets Healthcare Conference on Wednesday, November 17, 2010 at 3:15 p.m. EST from the St. Regis New York. A live webcast of the presentation can be accessed at www.marshalledwardsinc.com.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's pipeline is derived from an investigational isoflavone technology platform that has generated a number of compounds with anti-proliferative tumor activity. These small molecules have been shown to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. The Company's lead programs focus on two families of compounds with related but distinct mechanisms of action. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidates. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Marshall Edwards CEO to Present at JMP Securities Healthcare Conference
2. Protege of Nobel Prize Winner Robert Edwards Carries on his IVF Legacy
3. InterMune to Present at Canaccord Adams Conference
4. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
5. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
6. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
7. Bionovo to Present at Canaccord Adams Global Growth Conference
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 GliaCure, a privately-held biotechnology ... for neurological and neuropsychiatric disorders based on glial ... Alzheimer,s patients in a Phase 1b clinical trial ... developed as a potential disease-modifying treatment. GliaCure,s innovative ... that it both promotes the clearance of amyloid ...
(Date:5/4/2015)... - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, ... Roger J Garceau, to its Board of Directors. ... including corporate development and clinical strategy, his appointment ... expertise as Fluorinov transitions to clinical development.  ... pharmaceutical development experience to Fluorinov and most recently ...
(Date:5/4/2015)... 2015 Genedata, a leading provider ... life science research, today announced the release of ... of its enterprise solution for biologics R&D. This ... efficient discovery and development of novel biotherapeutics. Version ... address protein optimization and developability requirements. Genedata will ...
(Date:5/4/2015)... HONG KONG , May 4, 2015 ... or the "Company"), China,s leading ... cell processing and stem cell storage services, today announced ... Holdings Limited ("Golden Meditech"), a Hong Kong ... the Company, has entered into an agreement (the "Agreement") ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... -- 3SBio Inc. (NASDAQ: SSRX ) ... company focused on researching, developing, manufacturing and marketing ... its first quarter 2011 unaudited financial results after ... 11, 2011 at 8:00pm (US Eastern ). ...
... that a new market research report is available in ... Global Markets http://www.reportlinker.com/p0488650/Medical-Enzymes-Technologies-and-Global-Markets.html ... growing. The global market for medical enzymes is estimated ... at a compound annual growth rate (CAGR) of 3.9%, ...
... Novavax, Inc. (Nasdaq: NVAX ) will report financial ... 9, 2011, before the U.S. financial markets open.  The announcement ... by Stanley C. Erck, President and Chief Executive Officer, and ... The webcast and conference call will be ...
Cached Biology Technology:3SBio Inc. Schedules Unaudited First Quarter 2011 Results 2Reportlinker Adds Medical Enzymes: Technologies and Global Markets 2Reportlinker Adds Medical Enzymes: Technologies and Global Markets 3Reportlinker Adds Medical Enzymes: Technologies and Global Markets 4Reportlinker Adds Medical Enzymes: Technologies and Global Markets 5Reportlinker Adds Medical Enzymes: Technologies and Global Markets 6Reportlinker Adds Medical Enzymes: Technologies and Global Markets 7Reportlinker Adds Medical Enzymes: Technologies and Global Markets 8Reportlinker Adds Medical Enzymes: Technologies and Global Markets 9Reportlinker Adds Medical Enzymes: Technologies and Global Markets 10Reportlinker Adds Medical Enzymes: Technologies and Global Markets 11Reportlinker Adds Medical Enzymes: Technologies and Global Markets 12Reportlinker Adds Medical Enzymes: Technologies and Global Markets 13
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... of life, and occurs naturally in soil and ground water ... has been linked to lung, bladder and kidney cancer, and ... in drinking water. Chemically similar to phosphorus, arsenic forms arsenate ... 4 3- ). Arsenate interferes with many phosphate-requiring metabolic ...
... April 8 to 10, 2010, 185 attendees from 25 ... new tools to humanely and effectively manage populations of ... biology and other related scientific disciplines presented the newest ... health drug development. Veterinary leaders joined with animal welfare ...
... CORVALLIS, Ore. Forestry scientists at Oregon State University ... rate and other characteristics of trees can be changed ... is conceptually similar to traditional plant breeding. Cisgenics ... sexually compatible. If governments choose to regulate it similarly ...
Cached Biology News:Arsenic hyperaccumulating ferns: How do they survive? 2Arsenic hyperaccumulating ferns: How do they survive? 3Momentum builds after 4th International Symposium on Pet Contraception 2Momentum builds after 4th International Symposium on Pet Contraception 3Success with 'cisgenics' in forestry offers new tools for biotechnology 2Success with 'cisgenics' in forestry offers new tools for biotechnology 3
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Biology Products: